Elevance Sues CMS Over $115M in Medicare Advantage Star Ratings: A Bonus Payment Consistency Problem

Elevance Health sued the federal government on July 1, 2026 in the U.S. District Court for the Southern District of Georgia, alleging CMS's recalculation of 2026 Medicare Advantage star ratings cost it $115 million in quality bonus payments (STAT News, July 2, 2026). The claim: CMS dropped 20 disputed measures for Clover Health after losing that insurer's lawsuit, but declined to drop the same measures for Elevance's five affected contracts, even though Elevance performed well on them.

The Inconsistency at the Center of the Suit

The dispute traces back to a Georgia federal court ruling in late May 2026 that found CMS improperly included 20 measures in Clover Health's 2026 star rating calculation, split evenly between measures built on data CMS lacked statutory authority to collect and measures added without the notice-and-comment rulemaking the Administrative Procedure Act requires (Healthcare Dive, June 2026). CMS recalculated Clover's primary contract upward, from 3.5 to 4.5 stars, and then reran ratings for the rest of the industry the following month. But the agency applied a narrower fix everywhere else: for other insurers, it removed only the measures a judge had ruled it lacked authority to collect, not the ones invalidated on rulemaking grounds, while separately stripping a different set of measures, covering member complaints, voluntary disenrollment, and interpreter availability, from every plan's calculation (Healthcare Dive, July 2, 2026).

Elevance asked CMS on the same terms Clover received: recalculate our 2026 ratings using the full 20-measure removal, since our contracts scored well on the ones the agency chose not to drop for us. CMS denied that request on June 26, 2026, according to the complaint, which triggered the suit five days later. Docket 2:26-cv-00061 in the court's Brunswick Division names five Elevance Medicare Advantage contracts as directly affected (Health Care Litigation Tracker, Georgetown University, July 2026). Elevance's complaint frames the denial as arbitrary and capricious under the Administrative Procedure Act, the same statutory hook that won Clover its case, and argues CMS cannot apply one recalculation methodology to the plaintiff that sued and a different one to insurers that did not.

TD Cowen analyst Molly Turco captured the market's read on CMS's original response to Clover before Elevance filed: "CMS appears to concede on the data source argument and remove challenged measures as well as unchallenged measures" (TD Cowen, via Healthcare Dive, June 2026). That partial concession, dropping some measures industry-wide while withholding the rulemaking-based removals from everyone but the plaintiff, is exactly the asymmetry Elevance is now suing over.

From Quality Label to Rate Input: How a Star Tier Becomes $115 Million

The reason $115 million registers as a bid-level actuarial figure rather than a marketing footnote is mechanical. CMS's star rating program does not just publish a public-facing quality score; it feeds directly into the county benchmark math that determines an MA plan's allowable revenue. A contract at 4.0 stars or above receives a quality bonus payment equal to a five-percentage-point addition to its county benchmark, while a contract below 4.0 receives no bonus addition at all, and the same threshold simultaneously raises the share of the benchmark-to-bid savings a plan can return to members as rebate dollars, from 50% below 4.0 stars to 65% at 4.0 and 70% at 4.5 (CMS Rate Announcement, April 2026). Both the benchmark ceiling and the rebate percentage move at the same 4.0-star line, which is why a plan's star tier, not its raw score, is the number that actually clears through the bid.

That step function is what makes a measure-level dispute worth $115 million instead of a rounding error. A plan sitting near a star boundary does not lose value gradually as individual measures move against it; it loses the entire benchmark addition and the entire rebate-percentage upgrade the moment it falls on the wrong side of 4.0 or 4.5 stars. For Elevance, which improved dramatically on the metric that matters most to its 2026 bid book, roughly 53% of its 2.2 million Medicare Advantage members are now in plans rated 4 stars or higher, up from about 40% a year earlier (Modern Healthcare, July 2026), a handful of measures excluded from only five of its contracts is enough to swing tens of millions of dollars in benchmark and rebate revenue if those contracts sit near a threshold. The $115 million figure is not a communications number Elevance chose for a press release. It is the output of the same benchmark-and-rebate formula every MA actuary uses to translate a star rating into a bid assumption, run against the measure set CMS declined to apply.

Illustrative Benchmark and Rebate Swing by Star Tier, Per 100,000 Members
Star Rating	QBP Benchmark Addition	Rebate Return Rate	Annual Revenue Swing vs. Sub-4.0
Below 4.0 stars	None	50%	Baseline
4.0 stars	+5.0 ppts of county benchmark	65%	Roughly $36M in combined QBP and rebate lift
4.5 stars	+5.0 ppts of county benchmark	70%	Additional $10.8M in rebate lift over 4.0

Sources: CMS Rate Announcement (April 2026); CMS Part C bid framework. Illustrative figures assume a $1,200 county benchmark and $150 bid-to-benchmark spread across 100,000 members; actual results vary by contract geography and enrollment.

Scaled down to the five contracts named in Elevance's complaint, which collectively cover a fraction of its 2.2 million-member book, that same math produces a revenue swing in the tens of millions of dollars range without requiring any contract to cross a full star tier. A measure removal that shifts a contract's rounded score from 3.75 to 4.00 stars, or from 4.25 to 4.50, is enough on its own to trigger the benchmark and rebate step, which is why $115 million across five contracts is plausible even though the underlying measure changes look narrow, covering complaints, disenrollment, and interpreter access rather than a wholesale rewrite of clinical performance.

Three Straight Years of Litigation-Driven Recalculation

What separates this dispute from an isolated legal skirmish is that CMS has now been forced to redo Medicare Advantage star rating payments in three consecutive plan years. Successful lawsuits from SCAN Health Plan, Zing Health, and Elevance itself pushed CMS to recalculate 2024 star ratings, eventually adding roughly $1 billion in quality bonus payments across the industry (RISE Health, 2025). A second wave of litigation-driven adjustments followed for the 2025 plan year. The Clover ruling and the Elevance suit it produced now mark the third straight cycle in which a court, not CMS's own published methodology, has determined which measures actually count toward the ratings insurers bid against.

For a bid actuary, that pattern changes what a published star rating is allowed to mean as a modeling input. In a stable rulemaking environment, this year's rating is close to a known revenue quantity, and the actuary's job is to forecast next year's clinical and operational performance against a fixed measure set. Three consecutive years of court-ordered recalculation means the measure set itself is no longer fixed, so a 2027 bid built only on a performance forecast is missing a second, independent source of variance: whether the rating an insurer is bidding against will still exist in its published form by the time CMS finalizes 2027 ratings. Methodology risk has become a pricing input in its own right, not a legal curiosity to monitor from the sidelines.

Cut Points, Clustering, and Why Selective Measure Removal Spreads Beyond One Plan

The Elevance complaint raises a structural question that goes beyond fairness to any single insurer. CMS does not score most star rating measures against an absolute standard; it applies a clustering algorithm that groups plans into star tiers based on the distribution of scores across the entire national MA market for that measure and year. Removing a measure from the calculation for some plans but not others does not just change the numerator for the plans directly affected. It changes the population used to set every remaining measure's cut points, because the clustering runs on whichever plans and measures are actually in the calculation that year.

That is the deeper version of Elevance's inconsistency argument: a relative, cut-point-based rating system assumes every competitor is scored against the same measure set and the same comparison population. Once CMS starts removing different measures for different plans depending on who sued and who did not, the star tier a plan lands in is no longer purely a function of its own performance. It is partly a function of which of its competitors happened to litigate first and which measures a judge happened to strike for them specifically. A benchmark system built to allocate a finite pool of bonus dollars by relative quality tier cannot tolerate an input that varies by which plaintiff won which lawsuit, and Elevance's suit is the first to put that argument in front of a court rather than leaving it as an actuarial observation.

The three measures CMS did strip for every plan, complaints against the health plan, voluntary disenrollment, and interpreter availability, are operational and service-quality metrics rather than clinical outcome measures, and removing them industry-wide changes the weighting of the remaining measure set toward clinical and medication-adherence performance for every contract simultaneously. That uniform removal did not generate a lawsuit because it applied evenly. The 10 measures removed only for Clover on rulemaking grounds are the ones creating litigation risk, precisely because CMS chose to apply that removal to one plaintiff and withhold it from competitors bidding in the same counties against the same finite quality bonus pool.

Sizing the 2026 Quality Bonus Pool

The dollar figures at stake extend well past any single insurer's complaint. CMS will spend at least $13.4 billion on the Medicare Advantage quality bonus program in 2026, up from $12.7 billion in 2025 and more than four times the $3.0 billion the program cost in 2015 (KFF, July 2026). That growth has occurred even as the share of MA enrollees in a bonus-qualifying plan has fallen to 68% in 2026, down from 75% in 2025 and the lowest share since 2018 (KFF, July 2026), meaning the dollars are concentrating in a shrinking pool of higher-rated contracts rather than spreading further across the market. UnitedHealth Group receives the single largest dollar increase from the program, an estimated $3.9 billion, while Kaiser Foundation Health Plans receives the largest increase on a per-member basis, at $577 per enrollee (KFF, July 2026). Total quality bonus spending equals 2.3% of the $574 billion CMS projects paying Medicare Advantage plans overall in 2026 (KFF, July 2026), a small share of total MA spending that nonetheless represents the entire margin differential between a plan that clears 4.0 stars and one that does not.

Against that backdrop, the roster of insurers now suing CMS over star rating recalculation, Clover, CareFirst BlueCross BlueShield, and Elevance in 2026 alone, on top of SCAN, Zing Health, and Elevance's own earlier 2024 challenge, shows a growing share of a $13.4 billion pool being contested in federal court rather than settled through CMS's published methodology. Every insurer near a star threshold now has a live incentive to litigate rather than accept a published rating, because the dollar swing at stake and the precedent set by Clover's win make the expected value of a challenge difficult to ignore.

Building 2027 Bid Assumptions Around Methodology Risk

The practical task for an MA bid actuary heading into the 2027 cycle is to stop treating the current published star rating as a fixed revenue input and start carrying an explicit methodology-risk scenario alongside the usual clinical performance forecast. That means documenting, for any contract within roughly half a star of the 4.0 or 4.5 threshold, what the benchmark and rebate impact would be under at least three states of the world: CMS's methodology holds as published, CMS voluntarily broadens measure removal to resolve the Elevance-style inconsistency claim before 2027 ratings finalize, and a fourth consecutive year of court-ordered recalculation arrives after bids are locked. Each scenario carries a different revenue outcome and a different resubmission timeline, and a memorandum that only sensitizes clinical performance risk is not capturing the variance that has now materialized in three straight plan years.

The Elevance suit also gives actuaries a concrete precedent to price against rather than a hypothetical one. A plan that can show, the way Elevance did, that it performed well on measures CMS declined to remove has a quantifiable claim and a court willing to hear administrative-law arguments about consistency across insurers. That does not make litigation a certainty for every plan near a threshold, but it does mean the probability weight assigned to a favorable methodology outcome in a 2027 bid scenario matrix should reflect an active legal strategy insurers are now demonstrably willing to pursue, not a tail risk that can be assumed away.